ANDA 208060, held by Teva Pharms USA. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 208060 (Lurasidone Hydrochloride), held by Teva Pharms USA, was first approved by FDA on May 17, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2019 | Original application | Approved | None posted |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Discontinued |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Discontinued |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Discontinued |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Discontinued |
| Lurasidone Hydrochloride120MG · tablet;oral | Lurasidone Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters